NCT00906685

Bevacizumab for Central Retinal Vein Occlusion Study

A Prospective, Randomized, Controlled Study on Intravitreal Bevacizumab (Avastin) for Central Retinal Vein Occlusion (CRVO)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Anders Kvanta · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.

Conditions

• Central Retinal Vein Occlusion

Interventions

Type	Name	Description
DRUG	bevacizumab	Intravitreal injection of 1.25 mg bevacizumab
DRUG	Sham bevacizumab injection	Sham intravitreal injection

Timeline

• Start date: 2009-05-01
• Primary completion: 2011-03-01
• Completion: 2011-09-01
• First posted: 2009-05-21
• Last updated: 2011-11-22

Locations

1 site across 1 country: Sweden